@article{MohrScherrerAssafBenderBerkingChandwaniEigentlerGrimmelmannGutzmerHaferkampHasselHauschildHerbstJiangKählerKreplerKreuterLeiterLoquaiMeierPföhlerRudolphSchadendorfSchiavoneSchleyTerheydenUgurelUlrichUtikalWeishauptWelzelWeichenthal_2022,
title={Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany},
author={Mohr, Peter and Scherrer, Emilie and Assaf, Chalid and Bender, Marc and Berking, Carola and Chandwani, Sheenu and Eigentler, Thomas and Grimmelmann, Imke and Gutzmer, Ralf and Haferkamp, Sebastian and Hassel, Jessica C. and Hauschild, Axel and Herbst, Rudolf and Jiang, Ruixuan and Kähler, Katharina C. and Krepler, Clemens and Kreuter, Alexander and Leiter, Ulrike and Loquai, Carmen and Meier, Friedegund and Pföhler, Claudia and Rudolph, Anja and Schadendorf, Dirk and Schiavone, Maximo and Schley, Gaston and Terheyden, Patrick and Ugurel, Selma and Ulrich, Jens and Utikal, Jochen and Weishaupt, Carsten and Welzel, Julia and Weichenthal, Michael},
issn={2072-6694},
doi={http://dx.doi.org/10.22028/D291-35966},
series={7},
volume={14},
publisher={MDPI},
journal={Cancers},
year={2022}
}